DRUG APPLICATION FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN CHILDREN Russian patent published in 2021 - IPC C12N15/86 A61K39/215 A61P31/14 C12N7/00 

FIELD: biotechnology; immunology; virology.

SUBSTANCE: drug application for the prevention of diseases caused by the virus of severe acute respiratory syndrome SARS-CoV-2 in children older than 1 month is described. 6 variants of the application of the tool are presented, including component 1 in the form of an expression vector based on the genome of the recombinant human adenovirus strain of the 26th serotype, in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and/or component 2 in the form of an expression vector based on the recombinant genome human adenovirus strain of the 5th serotype, in which E1 and E3 regions with a built-in expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO are deleted: 3, and/or component 3 in the form of an expression vector based on the genome of the recombinant simian adenovirus strain of the 25th serotype, in which E1 and E3 regions with an integrated expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 are deleted. The claimed components are used both separately and jointly.

EFFECT: group of inventions provides the creation of a safe and effective remedy that ensures the development of humoral and cellular immune response reactions against the SARS-CoV-2 virus in children older than 1 month, the drug also provides the induction of a humoral immune response comparable to the immune response of an adult and provides an enhanced mucosal response in the respiratory tract.

15 cl, 6 dwg, 8 tbl, 16 ex